1. Home
  2. PLSE vs PHVS Comparison

PLSE vs PHVS Comparison

Compare PLSE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$14.60

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.99

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
PHVS
Founded
2014
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.7B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
PLSE
PHVS
Price
$14.60
$24.99
Analyst Decision
Buy
Buy
Analyst Count
1
9
Target Price
$22.00
$39.44
AVG Volume (30 Days)
199.0K
266.8K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$86,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,002.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$11.51
52 Week High
$25.00
$29.80

Technical Indicators

Market Signals
Indicator
PLSE
PHVS
Relative Strength Index (RSI) 53.11 48.62
Support Level $13.17 $23.62
Resistance Level $14.91 $26.77
Average True Range (ATR) 0.83 1.57
MACD 0.10 -0.16
Stochastic Oscillator 54.48 28.38

Price Performance

Historical Comparison
PLSE
PHVS

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: